Physician profile
Muhammad Hanif
NPI 1013999036
$4,727.14
in general payments reported to CMS, 2019-2025
42 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,267 · 2020: $1,065 · 2021: $744 · 2022: $477 · 2023: $514 · 2024: $372 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,174.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $724.18 | 2019-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Janssen Pharmaceuticals, INC | $543.76 | 2019-2022 | |
| Atricure, INC. | $390.15 | 2020 | |
| Sunovion Pharmaceuticals INC. | $320.64 | 2019-2021 | |
| Mylan Specialty L.P. | $261.07 | 2019-2024 | Yupelri |
| Shionogi INC | $213.86 | 2021-2025 | Fetroja |
| Avanir Pharmaceuticals, INC. | $164.95 | 2019-2022 | |
| Novo Nordisk INC | $163.67 | 2019-2022 | |
| Pfizer INC. | $160.15 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $154.45 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $151.76 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $134.29 | 2022-2024 | Rexulti, Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $123.86 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $123.34 | 2019-2023 | Verquvo |
| Allergan, INC. | $122.46 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Hanif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.